202 related articles for article (PubMed ID: 31572002)
21. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
[TBL] [Abstract][Full Text] [Related]
22. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
[TBL] [Abstract][Full Text] [Related]
23. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
[TBL] [Abstract][Full Text] [Related]
24. Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment.
Ando Y; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Ishikawa T; Nakano I; Hirooka Y; Goto H
Hepatol Res; 2018 Feb; 48(3):E240-E251. PubMed ID: 28865403
[TBL] [Abstract][Full Text] [Related]
25. Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure.
Shi H; Xiao G; Liao M; Zheng L; Jie Y; Lin G; Chong Y
Biomed Pharmacother; 2021 Feb; 134():111118. PubMed ID: 33341047
[TBL] [Abstract][Full Text] [Related]
26. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
27. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection.
Ke Y; Wang L; Li LQ; Zhong JH
World J Hepatol; 2014 Sep; 6(9):652-9. PubMed ID: 25276281
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
[TBL] [Abstract][Full Text] [Related]
29. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy.
Chen CH; Hu TH; Hung CH; Wang JH; Lu SN; Lee CM
J Viral Hepat; 2014 Aug; 21(8):e55-64. PubMed ID: 24766327
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy.
Gong WF; Zhong JH; Xiang BD; Li LQ
Mol Clin Oncol; 2016 Jul; 5(1):3-6. PubMed ID: 27330754
[TBL] [Abstract][Full Text] [Related]
31. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
Liu Y; Wang C; Zhong Y; Li X; Dai J; Ren X; Xu Z; Li L; Yao Z; Ji D; Wang L; Zhang L; Wong VW; Zoulim F; Xu D
J Viral Hepat; 2011 Apr; 18(4):e29-39. PubMed ID: 21392168
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
33. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
[TBL] [Abstract][Full Text] [Related]
34. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.
Qi W; Zhang Q; Xu Y; Wang X; Yu F; Zhang Y; Zhao P; Guo H; Zhou C; Wang Z; Sun Y; Liu L; Xuan W; Wang J
J Viral Hepat; 2020 Apr; 27(4):387-396. PubMed ID: 31755220
[TBL] [Abstract][Full Text] [Related]
35. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
[TBL] [Abstract][Full Text] [Related]
36. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
[TBL] [Abstract][Full Text] [Related]
37. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
[No Abstract] [Full Text] [Related]
38. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?
Wang CC; Kao JH
Expert Opin Pharmacother; 2016; 17(7):911-9. PubMed ID: 26831361
[TBL] [Abstract][Full Text] [Related]
39. Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone.
Oh MJ; Lee HJ
Saudi J Gastroenterol; 2016; 22(1):37-42. PubMed ID: 26831605
[TBL] [Abstract][Full Text] [Related]
40. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
Qi W; Shen J; Dai J; Wu Y; Zhang Y; Leng S; Gao F; Ran S; Peng W; Zhang X; Wen T; Li C
Cancer Med; 2021 Dec; 10(23):8421-8431. PubMed ID: 34643050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
